Back in November 2020, Cassava priced its public offering at $8 per share. Proceeds of $75 million were meant to support the Phase 3 study. Since then, SAVA stock has traded as high as $146, without a ...
WASHINGTON, July 27 (Reuters) - The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc (SAVA.O), opens new tab involving whether the biotech company manipulated ...
Cassava Sciences' presentation at the CTAD Conference undermines its claim that simufilam is an effective treatment for Alzheimer's Disease. The drug appears to have little to no effect on moderate ...
March 25 (Reuters) - Cassava Sciences (SAVA.O), opens new tab said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory scrutiny, failed in a second late-stage study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback